Takeda Pharmaceutical’s blood pressure drug Edarbi has been approved by the FDA, according to PharmaTimes.

The agency has approved Edarbi (azilsartan), an angiotensin II receptor blocker, as a once-daily oral therapy for hypertension. The approval is based on seven phase III trials involving 5,900 patients that showed its superiority to placebo and the highest approved doses of two commonly-prescribed ARBs.